Applied DNA Sciences Inc ( APDN ) shares are trading higher by 6.0% to $1.76 during Tuesday’s session after the company announced it positioned its TR8 PGx testing as pre-emptive testing for therapeutic safety.

What To Know: Applied DNA Sciences ( APDN ) on Tuesday announced that its subsidiary, Applied DNA Clinical Labs (ADCL), is refining its TR8 PGx pharmacogenomics testing service by offering specialized subpanels for specific medical conditions.

The first subpanel targets patients with DPYD gene variants, which can affect metabolism of chemotherapy drugs fluorouracil (5-FU) and capecitabine (Xeloda), potentially leading to severe toxicities. This move follows an FDA safety notice emphasizing the risks for patients with DPD enzyme deficiencies.

ADCL's TR8 PGx test, approved in New York, screens for over 33 drug metabolism genes. CEO Dr. James A. Hayward highlighted plans for additional subpanels in oncology, cardiology and psychiatry to enhance clinical decision-making and increase adoption of PGx testing.

Read Also: What’s Going On With Rigetti Computing Stock Today?

How To Buy APDN Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Applied DNA Sciences’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, APDN has a 52-week high of $460.00 and a 52-week low of $1.45.